ArticlePeerJ2017
Mode of action of the 2-phenylquinoline efflux inhibitor PQQ4R against
Article in PeerJ, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Antimicrobial and Anti-Efflux Machinery of FDA-Approved Proton Pump Inhibitors and Vitamins AgainstMicroorganisms · 2025Article
- Chemical linkers switch triglycerol detergents from bacterial protein purification to mild antibiotic amplification.Communications chemistry · 2025Article
- Screening and Evaluation of Potential Efflux Pump Inhibitors with a Seaweed Compound Diphenylmethane-Scaffold against Drug-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Pyrrole-based inhibitors of RND-type efflux pumps reverse antibiotic resistance and display anti-virulence potential.PLoS pathogens · 2024Article
- Efflux pump inhibitory potential of indole derivatives as an arsenal againstMicrobiology spectrum · 2023Article
- Proton Motive Force Inhibitors Are Detrimental to Methicillin-Resistant Staphylococcus aureus Strains.Microbiology spectrum · 2022Article
- Phenolic Compound Ethyl 3,4-Dihydroxybenzoate Retards Drug Efflux and Potentiates Antibiotic Activity.Antibiotics (Basel, Switzerland) · 2022Article
- Repurposing Approved Drugs as Fluoroquinolone Potentiators to Overcome Efflux Pump Resistance in Staphylococcus aureus.Microbiology spectrum · 2021Article
- Microbial Efflux Pump Inhibitors: A Journey around Quinoline and Indole Derivatives.Molecules (Basel, Switzerland) · 2021Review
- Identified Seaweed Compound Diphenylmethane Serves as an Efflux Pump Inhibitor in Drug-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Antimicrobial activity and mode of action of 1,8-cineol against carbapenemase-producing Klebsiella pneumoniae.Scientific reports · 2021Article
- Antifungal Azoles as Tetracycline Resistance Modifiers in Staphylococcus aureus.Applied and environmental microbiology · 2021Article
- Antibacterial Activity and Mode of Action of β-caryophyllene onPolish journal of microbiology · 2020Article
- Sodium Hyaluronate Nanocomposite Respirable Microparticles to Tackle Antibiotic Resistance with Potential Application in Treatment of Mycobacterial Pulmonary Infections.Pharmaceutics · 2019Article
- Efflux pump inhibitors for bacterial pathogens: From bench to bedside.The Indian journal of medical research · 2019Review
- Flow Cytometric Analysis of Efflux by Dye Accumulation.Frontiers in microbiology · 2019Article
- Exposure to Sub-inhibitory Concentrations of the Chemosensitizer 1-(1-Naphthylmethyl)-Piperazine Creates Membrane Destabilization in Multi-Drug ResistantFrontiers in microbiology · 2019Article
- Microbe-Derived Indole Metabolite Demonstrates Potent Multidrug Efflux Pump Inhibition inFrontiers in microbiology · 2019Article
- Thermodynamic secrets of multidrug resistance: A new take on transport mechanisms of secondary active antiporters.Protein science : a publication of the Protein Society · 2018Review
- Identification of a Novel Polyamine Scaffold With Potent Efflux Pump Inhibition Activity Toward Multi-Drug Resistant Bacterial Pathogens.Frontiers in microbiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Efflux pump inhibitors are of great interest since their use as adjuvants of bacterial chemotherapy can increase the intracellular concentrations of the antibiotics and assist in the battle against the rising of antibiotic-resistant bacteria. In this work, we have described the mode of action of the 2-phenylquinoline efflux inhibitor (4-(2-(piperazin-1-yl)ethoxy)-2-(4-propoxyphenyl) quinolone - PQQ4R), against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.